Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

News

Sygnature is proud of its many achievements, research collaborations and awards and delighted to publish these achievements wherever possible. Below you can read and hear about exciting new developments within the organization.

Filter by:

News

Sygnature Discovery Adopts OpenEye’s Orion™ Platform to Strengthen Molecular Design Services

READ ARTICLE

Awards News

Sygnature Discovery shortlisted for BioNow Company of the Year Award

READ ARTICLE

News

Sygnature upgrades western blotting capability with Jess instrument from Protein Simple

READ ARTICLE

News

Dr Paul Overton becomes Chief Commercial Officer (CCO) at Sygnature

READ ARTICLE

News

£3M investment to expand high-throughput screening and translational oncology capabilities

READ ARTICLE

News

What happened? A 2020 Recap!

READ ARTICLE

News

Sygnature Discovery wins Medilink Outstanding Achievement Award

READ ARTICLE

News

Sygnature Discovery expands DMPK capabilities with acquisition of XenoGesis

READ ARTICLE

News

Sygnature and RenaSci strengthen drug abuse leadership with appointment of Dr Andy Mead

READ ARTICLE

News

Sygnature Discovery boosts senior management team with appointment of Dr Paul Overton

READ ARTICLE

Drug Discovery News

Sygnature assists New York Medical College in the fight against Covid-19

READ ARTICLE

News Therapeutic Areas

Sygnature expands capabilities with acquisition of Alderley Oncology

READ ARTICLE
MORE...